Using biosamples from a phase II open-label study of the interleukin 1 (IL-1) receptor antagonist (IL-1Ra) anakinra in treating IVIG-resistant Kawasaki Disease (KD) patients, we recently identified leucin-rich-α2-glycoprotein-1 (LRG-1) as known trigger of endothelial activation and cardiac re-modelling to associate with IL-1β signaling in KD. The gene discussed is IL1B; the disease is Kawasaki disease.